Payment overview · 2025
General Payments
$641.00
40 reported records · 16 companies
Healthcare provider profile · identity verified
David R Allen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOLTON, KS · NPI 1952371163
Verified facts
What the public records show
CMS Open Payments records show David R Allen, M.D. received $641.00 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.55 | 26.6% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.61 | 9.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.93 | 9.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.57 | 7.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.95 | 7.0% | 3 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $33.88 | 5.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $30.43 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.10 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.03 | 4.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.35 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.76 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.88 | 3.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.97 | 3.0% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.32 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.91 | 2.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.76 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $641.00 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $88.57 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.98 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.30 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.61 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.93 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.57 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.35 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 355 | 73 |
| Potassium Chloride | Potassium Chloride | 265 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 68 |
| Gabapentin | Gabapentin | 236 | 49 |
| Furosemide | Furosemide | 230 | 48 |
| Omeprazole | Omeprazole | 229 | 45 |
| Lisinopril | Lisinopril | 224 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 214 | 37 |
| Metformin Hcl | Metformin Hcl | 190 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 44 |
| Losartan Potassium | Losartan Potassium | 147 | 39 |
| Tramadol Hcl | Tramadol Hcl | 135 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 32 |
| Allopurinol | Allopurinol | 118 | 23 |
| Warfarin Sodium | Warfarin Sodium | 114 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 18 |
| Carvedilol | Carvedilol | 99 | 25 |
| Sertraline Hcl | Sertraline Hcl | 99 | 25 |
| Simvastatin | Simvastatin | 95 | 29 |
| Prednisone | Prednisone | 90 | 46 |
| Meloxicam | Meloxicam | 85 | 20 |
| Glimepiride | Glimepiride | 81 | 18 |
| Metformin Hcl Er | Metformin Hcl | 80 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Montelukast Sodium | Montelukast Sodium | 66 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Jardiance | Empagliflozin | 63 | 16 |
| Fentanyl | Fentanyl | 62 | suppressed |
| Clonazepam | Clonazepam | 60 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 12 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Trazodone Hcl | Trazodone Hcl | 55 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Benazepril Hcl | Benazepril Hcl | 52 | suppressed |
| Alprazolam | Alprazolam | 51 | 15 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Atenolol | Atenolol | 50 | 11 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 22 |
| Azithromycin | Azithromycin | 46 | 37 |
| Cephalexin | Cephalexin | 46 | 30 |
| Eliquis | Apixaban | 46 | 11 |
| Ezetimibe | Ezetimibe | 46 | 11 |
| Ozempic | Semaglutide | 46 | suppressed |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 20 |
| Topiramate | Topiramate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $641.00 · 40 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EOHILIA, EVENITY, FANAPT, HETLIOZ, JARDIANCE, Kimyrsa, LEQVIO, MOUNJARO, OTEZLA, Ohtuvayre, Orbactiv, QULIPTA, REPATHA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error